Skin Cancer

As we wrap up July, explore the new sunscreen ingredient approval, debunk summer skin care myths, and learn how UV damage and therapies are shaping skin cancer prevention today.

Our July issue tackles melanoma surgery challenges, melasma in skin of color, new bemotrizinol sunscreen, atopic dermatitis breakthroughs, and billing insights from Whitney Hovenic, MD, Joseph Gatti, DMSc, Rivkah Epstein, PA-C, and more.

New trends around cheeky swimwear and tanning myths are leading to rising rates of melanomas in sensitive areas; read July's cover story to learn more.

Long-term TNF inhibitor use was associated with significantly increased risks of melanoma and nonmelanoma skin cancer in a large cohort study.

Dermatologists and oncologists at a Dermatology Times Evolving Paradigms event in Boston compared immunotherapy selection, referral practices and surveillance strategies in advanced cutaneous squamous cell carcinoma.

Dermatologists and oncologists at a Dermatology Times Evolving Paradigms event in Dallas compared immunotherapy selection, adverse event management, and referral practices in advanced cutaneous squamous cell carcinoma.

Kathleen Suozzi, MD, details how she debunks sunscreen myths, explains absorption and SPF, urges year‑round UV habits, and previews new filter bemotrizinol, when counseling her own patients.

Kathleen Suozzi, MD, explains how UV damage shows up, why actinic keratoses matter, and which field therapies and lasers help cut skin cancer risk.

At a recent Dermatology Times Evolving Paradigms event led by Mark Nestor, MD, PhD, FAAD, dermatologists, Mohs surgeons, and oncologists compared immunotherapy mechanisms and referral thresholds for advanced CSCC.

Black Girl Sunscreen founder Shontay Lundy debunks SPF myths for skin of color, urging education, representation, and teamwork for healthier skin.

Konika Patel Schallen, MD, discussed new findings showing the Nordlys 1940 nm non-ablative fractional laser may reverse epigenetic markers of skin aging in a recent Dermatology Times interview.

In this episode, Black Girl Sunscreen CEO Shontay Lundy reveals why skin of color needs photoprotection, better formulas, and stronger clinician-industry collaboration.

At a recent Dermatology Times Evolving Paradigms event, Nikhil Khushalani, MD, led dermatologists, Mohs surgeons, and oncologists in comparing systemic immunotherapy selection, referral practices, and adverse event management in advanced cutaneous squamous cell carcinoma.

The FDA has accepted Replimune's third resubmitted BLA for RP1 plus nivolumab in advanced melanoma, setting an August 2 PDUFA date.

An Evolving Paradigms event led by Darrell S. Rigel, MD, MS, compared PD-1/PD-L1 immunotherapies for advanced cutaneous squamous cell carcinoma, with referral guidance and toxicity alerts.

State melanoma reporting data reveals a striking gap between one Arizon dermatologist's detection rates and his peers, and a possible explanation rooted in how dermoscopy is taught.

New data show that nearly two-thirds of Sun Bus participants had never visited a dermatologist, highlighting persistent gaps in access to skin cancer care.

Neal Bhatia, MD, led an Evolving Paradigms event on advancing multidisciplinary care in cutaneous squamous cell carcinoma to compare systemic immunotherapy data and referral practices.

Microneedle SkinJect patch aims to clear basal cell carcinoma without surgery, showing phase 2 promise and expanding to Gorlin syndrome trials.

Dissolvable microneedles deliver doxorubicin to basal cell lesions, showing promising phase 2 clearance and opening hope for Gorlin syndrome patients.

Cosibelimab joins cemiplimab and pembrolizumab as a first-line option for advanced cSCC unsuitable for curative surgery or radiation.

Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.

The June issue of Dermatology Times highlights the latest advances in skin cancer, psoriasis, atopic dermatitis, hidradenitis suppurativa, and emerging dermatology technologies.

Deborah Sarnoff, MD, president of the Skin Cancer Foundation, discusses actinic keratosis detection, treatment, and clinician resources provided by the Skin Cancer Foundation.

Miriam Pomerantz Kadosh, MSW, LCSW, director of education and patient engagement at the Melanoma Research Foundation, outlines free resources available to dermatology practices and communities.